Dexcom Inc Stock Price, News & Analysis

Dexcom, Inc. (NASDAQ: DXCM) celebrates the expansion of coverage for its continuous glucose monitoring system under the Non-Insured Health Benefits (NIHB) program in Canada. This decision allows all insulin-dependent diabetes clients to access the Dexcom G6 system, significantly improving diabetes management for First Nations and Inuit peoples. Previously announced changes in coverage criteria now ensure a higher degree of accessibility to critical healthcare technology. Leading medical professionals advocate this technology's benefits for managing diabetes effectively. The Dexcom G6 provides real-time glucose data and alerts, facilitating better diabetes care and potentially reducing long-term complications. Dexcom's commitment to improving health outcomes is further emphasized by comparisons to similar expansions in U.S. coverage by CMS.

Dexcom (NASDAQ: DXCM) announces the expansion of Medicare coverage for its continuous glucose monitoring (CGM) system, the Dexcom G7, to include all insulin users and certain non-insulin users. This change grants approximately 1.5 million additional Medicare patients in the U.S. access to the most accurate CGM available without extra costs compared to other brands. The MOBILE study provided critical clinical evidence demonstrating significant improvements in A1C levels and time in range for users. Dexcom emphasizes the affordability and ease of use of its products, as the Dexcom G7 has a MARD of 8.2% and is set up easily. The updated policy is regarded as the most significant single expansion of CGM coverage to date, potentially improving the quality of life for millions of diabetes patients.

DexCom, Inc. (NASDAQ:DXCM) will announce its first quarter 2023 financial results on April 27, 2023, after market close. Management will host a conference call at 4:30 p.m. ET to discuss performance, which will also be available via webcast on the investors.dexcom.com site. Participants can listen by dialing (888) 414-4585 for US/Canada or (646) 960-0331 for international calls, using the confirmation ID "9430114". As a leader in diabetes care, DexCom focuses on empowering users through continuous glucose monitoring (CGM) systems, enhancing diabetes management globally.

Dexcom has announced that its G6 Continuous Glucose Monitoring (CGM) System will now be available to individuals of all ages with type 1 and type 2 diabetes in Manitoba. This update, effective from March 14, 2023, allows eligible patients to access the device without needing preapproval, enhancing accessibility and reducing the administrative burden on healthcare providers. By expanding access to real-time glucose monitoring, Manitoba positions itself as a leader in Canada, promoting better diabetes self-management and potentially lowering emergency care needs related to severe hypoglycemia.

DexCom, Inc. (NASDAQ: DXCM) reassures stakeholders amid speculation regarding its relationship with Silicon Valley Bank (SVB) following recent developments. The company clarifies it has no material exposure to SVB, holding about $2.5 billion in cash and short-term marketable securities, of which only $2.7 million is at SVB. DexCom emphasizes its diversified banking relationships, ensuring that it is not reliant on SVB. This communication aims to maintain investor confidence and highlight the company's robust financial position.

DexCom, Inc. (NASDAQ:DXCM) announced its participation in two upcoming investor conferences. Sean Christensen, Vice President of Finance and Investor Relations, will present at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023, at 2:45 PM EST. Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present at the Raymond James 44th Annual Institutional Investors Conference on March 7, 2023, at 3:25 PM EST. Webcast links will be available on the Dexcom Investor Relations website and archived for future access.

Dexcom, Inc. (NASDAQ: DXCM) is set to showcase its continuous glucose monitoring (CGM) portfolio at the 16th International Conference on Advanced Technologies and Treatments for Diabetes in Berlin from February 22-25, 2023. The company reports the successful launch of Dexcom G7 in eight countries and highlights the growing significance of Dexcom ONE in expanding CGM access, impacting over 3.5 million lives globally. Initial feedback on Dexcom G7 indicates high user satisfaction with its features, including a 60% smaller design and a market-leading warmup time of 30 minutes. Dexcom G6 continues to excel in connectivity, facilitating integration with various insulin delivery systems.

The U.S. Centers for Medicare & Medicaid Services has approved coverage for the Dexcom G7, a continuous glucose monitoring system designed for diabetes management. Launching on February 17, 2023, the G7 is touted as the most accurate CGM, eliminating routine fingersticks and offering real-time glucose readings. This approval cements Dexcom's position as a leading CGM provider, making the G7 accessible to Medicare patients. The device features a 30-minute sensor warm-up, smaller design, and improved app integration, enhancing user experience and diabetes management.